Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab

JAMA Oncol. 2021 Feb 1;7(2):309. doi: 10.1001/jamaoncol.2020.6989.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Decision-Making
  • Humans
  • Ipilimumab
  • Neoadjuvant Therapy*
  • Nivolumab*

Substances

  • Ipilimumab
  • Nivolumab